
Gilead Sciences (NASDAQ:GILD) expects its expanding HIV prevention portfolio and a potential new cell therapy for multiple myeloma to support growth, even as a negotiated price change for its HIV treatment Biktarvy creates an anticipated $1.5 billion headwind in 2028, Chief Financial Officer Andy Dickinson said at an investor conference.
Speaking with UBS Senior Biotechnology Analyst Michael Yee, Dickinson said Gilead expects its base business, excluding the COVID-19 antiviral Veklury, to grow 10% to 11% in 2026. He declined to provide 2027 guidance but said the company expects growth in its HIV business, overall business and earnings per share in 2028 despite the Biktarvy impact.
HIV Prevention Launches
Dickinson said Gilead is targeting approximately $1 billion in 2026 sales for Yeztugo, its twice-yearly injection for HIV pre-exposure prophylaxis, or PrEP. That is up from an initial target of approximately $800 million, he said.
More than 70% of patients have returned for their second Yeztugo injection, a higher persistence rate than the company expected, Dickinson said. He added that two-thirds to three-quarters of people moving to Yeztugo are switching from daily oral medications, while more patients new to HIV prevention are starting the injectable than Gilead anticipated.
Gilead expects about $3 billion in PrEP sales from its daily oral drug Descovy this year, bringing the company’s HIV prevention business to roughly $4 billion, Dickinson said. He estimated that 600,000 to 700,000 people are using PrEP, most of them daily pills, compared with the 2.2 million people the Centers for Disease Control and Prevention believes should be on HIV prevention.
A weekly oral version of Yeztugo has a February regulatory decision date. Dickinson said the application draws in part on data from patients in the PURPOSE studies who received the weekly oral drug during a clinical hold related to questions about glass vials. The company waited until it had alignment with the Food and Drug Administration and the filing was accepted before disclosing the program, he said.
Dickinson said the weekly pill could attract users of both Descovy and generic Truvada, but he declined to provide launch guidance. Gilead also expects to launch a yearly injectable prevention option in 2028.
Multiple Myeloma Therapy Awaits Decision
Gilead expects a December 23 regulatory decision on anito-cel, a BCMA-directed CAR T-cell therapy for multiple myeloma. Dickinson said the company anticipates an initial label for patients in the fourth line of treatment or later and expects a strong launch if the therapy is approved.
Dickinson said Gilead believes anito-cel has a competitive efficacy profile and a differentiated safety profile compared with rival Carvykti. He said Gilead had not seen signs of the long-term neurological side effects associated with some competing regimens, while noting that anito-cel has shown other side effects associated with CAR T therapies.
Updated data, including progression-free survival curves, are expected at the American Society of Hematology meeting, he said. Gilead also expects data next year from a fully enrolled study in earlier-line patients.
Dickinson said the company expects anito-cel to become the leading CAR T therapy in the fourth-line-and-later market within 18 months, although obtaining formulary access at major treatment centers could take up to six months. He said Gilead does not expect FDA manufacturing limits to constrain the launch.
Pricing and Pipeline Outlook
Some of Gilead’s recent growth has benefited from favorable pricing, particularly as more Descovy sales have shifted toward prevention patients with commercial insurance, Dickinson said. He cautioned that the benefit could moderate, while saying most HIV growth this year has been driven by demand and volume.
Dickinson also highlighted early immunology programs, including the oral ?4?7 drug emvistegrast, an IL-23 peptide Gilead is acquiring, and an IRAK4 inhibitor being advanced into a phase 2b study after a small trial in cutaneous lupus. He said Gilead is exploring potential combinations and partnerships involving emvistegrast.
About Gilead Sciences (NASDAQ:GILD)
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.
